NCT03164057 2026-01-28
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT06221683 2024-08-22
GMCAII
Children's Hospital of Soochow University
Phase 2 Recruiting
NCT06532084 2024-08-01
SoraGVL
St. Petersburg State Pavlov Medical University
Phase 2 Recruiting
NCT02135874 2024-03-22
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01253070 2022-08-04
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT04752527 2021-11-15
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03170895 2020-03-30
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Completed
NCT02196857 2020-01-14
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00510289 2016-04-19
Sorafenib in Myelodysplastic Syndrome
Duke University
Phase 2 Terminated
NCT00893373 2016-02-05
SORAML
Technische Universität Dresden
Phase 2 Completed
NCT01510756 2016-01-21
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Terminated
NCT00131937 2015-09-03
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00661180 2014-12-23
ORACLE
Bayer
Phase 2 Completed
NCT00303966 2014-05-07
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00373373 2009-08-19
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
University Hospital Muenster
Phase 2 Completed